Pfizer disclosed Phase 2 data from the monthly GLP‑1 acquired through its $10 billion Metsera purchase, reporting clinically meaningful weight loss and confirming the drug's potential as a once‑monthly maintenance therapy. The company reported placebo‑adjusted weight reductions as high as 12.3% in one cohort at 28 weeks and another dataset showing 10.5% at six months, outcomes Pfizer says support a broad phase‑3 program. Pfizer plans an expanded Phase 3 program testing higher maintenance doses to chase greater weight loss efficacy and differentiation vs. weekly GLP‑1s. The data have tempered investor doubts while sharpening the competitive landscape in obesity therapeutics, where dose, durability, and dosing cadence remain pivotal commercial differentiators.